Sacha was most recently the CEO of Biosys UK Limited, a clinical stage microbiome company developing oral polyclonal antibodies as targeted gut modulators for various indications. She raised venture financing, optimized production and CMC, designed and successfully executed a novel confirmatory study, engaged with and secured regulatory feedback from EMA and Dutch agencies, and prepared the C.difficile program for a late stage clinical trial. Previously Sacha was with Inventages (global life science fund with $1.5B AUM) and led investments focused on the microbiome, GI disorders, CNS, anti-infectives, inflammatory diseases, metabolic disorders, renal disorders, vaccines, and point of care diagnostics. She transitioned to a Venture Partner role with Inventages when she became the CEO of Biosys UK Limited.
Prior to Inventages, Sacha was an early stage investor focused on innovation, company formation and investment in the UK (Archangels) and Canada (BDC Capital). Sacha was directly involved in establishing university spin-offs and has experience in biotech business development, corporate finance, management consulting and R&D. Sacha has a MBA (Simon Fraser University), a MSc in Biotechnology (Johns Hopkins University), a BSc in Chemistry (University of British Columbia), and is a Kauffman Fellow. She founded the C100 in the UK to support the growth of Canadian entrepreneurs as they scale their businesses into Europe.